{"prompt": "['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'laboratory tests:', 'hematology: a complete blood count with hemoglobin level,', 'serum biochemistry including levels of: creatinine, urea, bilirubin, AST, ALT, LDH, TSH,', 'alkaline phosphatase (ALP) albumin, sodium, potassium, calcium (total),', 'coagulation: Activated Partial Thromboplastin Time (APTT), International Normalized', 'Ratio (INR)', 'routine urine analysis,', 'serum \u00df-HCG pregnancy test in fertile females,', 'HIV testing by the enzyme-linked immunosorbent assay (ELISA) +/- Western blot.', 'filling in EORTO QLQ-C30 and FKSI questionnaires,', 'filling in the PSS questionnaire,', 'collection of blood samples for serum biomarkers,', 'collection of formalin-fixed paraffin embedded primary tumour tissue whenever available.', 'Corrected calcium level will be calculated using formula:', 'Corrected calcium level [mg/dl] = total calcium level [mg/dl] + 0.8 X (4.0 - albumin level [g/dL])', 'Within 4 weeks before the start of therapy, baseline tumor measurement(s) will be performed on', 'each patient. Computed tomography (CT) and magnetic resonance imaging (MRI) are allowed', 'methods of measurement. The study will not permit ultrasound, chest-X-ray or positron emission', 'tomography (PET) scans as methods of tumor measurement.', '6.6.2 Treatment Period', 'During every day of the treatment period, patient will have to collect blood pressure and pulse', 'measures two times a day (in the morning and in the evening) and to record the results in the', \"Patient's Diary.\", 'The examinations and investigations during control visits, that will take place every 6 weeks of', 'treatment, will include:', 'physical examination,', 'vital signs measurement,', 'laboratory tests:', 'hematology: a complete blood count with hemoglobin level,', 'Page 32 of 60']['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'serum biochemistry including levels of: creatinine, urea, bilirubin, AST, ALT, ALP, LDH,', 'albumin, sodium, potassium, calcium (total),', 'standard 12- - lead ECG,', 'filling in the EORTO QLQ-C30 and FKSI-15 questionnaires,', 'filling in the PSS questionnaire.', 'At the start of the second and third week of the treatment (W2D1 and W3D1), additional visit is', 'planned to assess safety of propranolol and to define further propranolol dose and will include', 'physical examination, vital signs measurement, verification of ambulatory blood pressure and pulse', 'measures, ECG (12-lead) and optional cardiology consultation.', 'Blood samples for serum biomarkers will be obtained at W7D1.', 'The method used at baseline to assess tumor measurement(s) must be used consistently and will be', 'repeated every 12 weeks (+ 2 weeks). Tumor responses will be measured and recorded using the', 'RECIST guidelines (version 1.1).', '6.6.3 Postdiscontinuation Period', 'Patients will continue treatment until they require discontinuation of study drugs for any reason', 'mentioned in Section 4.5.1 of this document (including disease progression). Each enrolled patient', 'will enter a postdiscontinuation period once study treatment is discontinued. The end-of-treatment', 'visit will take place within 30 days after discontinuation of the study drugs and will include:', 'physical examination,', 'vital signs measurement,', 'laboratory tests:', 'hematology: a complete blood count with hemoglobin level,', 'serum biochemistry including levels of: creatinine, urea, bilirubin, AST, ALT, ALP, LDH,', 'TSH, albumin, sodium, potassium, calcium (total),', 'coagulation: APTT, INR,', 'standard 12- - lead ECG,', '24-hour Holter ECG monitoring,', 'echocardiography,', 'cardiology consultation,', 'filling in the EORTC QLQ-C30 and FKSI-15 questionnaires,', 'Page 33 of 60']\n\n###\n\n", "completion": "END"}